Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FB102 Single and Multiple Dose Study in Healthy Volunteers
NCT07623057Phase 1Recruiting
- Sponsor
- Forte Biosciences, Inc.
- Start
- Jun 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FB102 (4 arms), sponsored by Forte Biosciences, Inc. Primary endpoints: Incidence, severity, and relationship to treatment of treatment-emergent adverse events and Incidence, severity, and relationship to treatment of serious adverse events. Started Jun 2026; status: recruiting.
02
Drugs
FB102
Beyond the preview
Go deeper on NCT07623057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07623057.